Blog

ESMO updates from Presidential Symposium- European Society for Medical Oncology (ESMO)

Photo taken from dailyreporter.esmo.org

Oct 24, 2023, 14:57

ESMO updates from Presidential Symposium- European Society for Medical Oncology (ESMO)

“Positive outcomes in advanced or metastatic urothelial carcinoma reported from EV-302/KEYNOTE-A39 and CheckMate 901 indicate immunotherapy and Antibody Drug Conjugates (ADCs) as an alternative to first-line chemotherapy for the first time.

Results presented at today’s Presidential Symposium at ESMO23 show that enfortumab, vedotin plus pembrolizumab and adding nivolumab to chemotherapy prolonged median Progression-free survival (PFS) and median overall survival (OS) compared with chemotherapy.

Andrea Apolo, Bethesda, USA, comments on these findings on the ESMO Daily Reporter.
Read the full article here.”

Source:

Andrea Apolo Antibody Drug Conjugates (ADCs) Bethesda cancer ESMO Daily Reporter ESMO23 European Society for Medical Oncology (ESMO) immunotherapy OncoDaily Oncology

Oncologist Near Me - Vivek Subbiah: Pionner of Precision Oncology

Monica Bertagnolli is ending her tenure as NIH director

NEW PAPER ALERT: Efficacy of CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2- Advanced Breast Cancer by PAM50 Subtype: SOLTI-1801 CDK-PREDICT Results

Oncologist Near Me – Fabrice André: Leading Expert in Breast Cancer

Funding Impactful Cancer Research That Might Otherwise Go Unsupported: Ryan Schoenfeld on the Secret Behind Mark Foundation’s Success

Special Coverage